Advertisement
Screener

CYPHERPUNK TECHNOLOGIES INC. (CYPH) Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost

2.8 / 5 stars · 68/120 Roast Me

CYPHERPUNK TECHNOLOGIES INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost

CYPHERPUNK TECHNOLOGIES INC. (CYPH) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $3.96 million as of 2025-12-31, per its 10-K filed 2026-03-16.

Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense

us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-16

  • 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.96M.
  • 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $6.70M.
  • 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $5.81M.
  • 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.76M.
Period endDeferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
2025-12-31$3.96M
10-K · filed 2026-03-16
2024-12-31$6.70M
10-K · filed 2026-03-16
2023-12-31$5.81M
10-K · filed 2025-03-26
2022-12-31$4.76M
10-K · filed 2024-03-18
2021-12-31$4.67M
10-K · filed 2023-03-24
2020-12-31$3.76M
10-K · filed 2022-03-11
2019-12-31$2.58M
10-K · filed 2021-03-12
2018-12-31$1.63M
10-K · filed 2020-03-16
2017-12-31$1.35M
10-K · filed 2019-04-01
2016-12-31$43.00K
10-K · filed 2018-02-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06